Mesothelioma Clinical Trials

A mesothelioma diagnosis is a serious one, but it is not one without hope. There are a variety of treatments available, and a number of ongoing clinical trails.

Trial Status

We do our best to keep the current status (closed, currently recruiting, upcoming) of each clinical trial up-to-date. Several clinical trials are listed at ClinicalTrials.gov as "currently recruiting" despite the estimated completion date having been long past. The contact for a particular clinical trial is your best bet to discover if a particular clinical trial is still open and recruiting.

Glossary

To help you as you read through these clinical trials, we have glossary of terms and their definitions. Words underlined with a dashed line are part of the glossary; to see their definition, simply click on the word.

Clinical Trials

Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)

Primary Outcome Measures Study related adverse events (AEs) [ Time Frame: Each subjects will be assessed for AEs from the time of their first study treatment until 30 days after the end of their treatment for AEs and until 90 days after their last treatment for serious AEs (study treatment may ... [More >>]

A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors

Primary Outcome Measures Adverse Events (Part 1 and Part 2) [Time Frame: Approximately 24 months] Objective response rate (ORR) (Part 2) [Time Frame: Approximately 24 months] Secondary Outcome Measures Maximum observed concentration (Cmax) of rebastinib [ Time Frame: Cycle 1 Day 1, Cycle 2 Day 1 (each cycle is 21 days) ] Measure the Cmax Area ... [More >>]

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Primary Outcome Measures Frequency and severity of adverse events of INBRX-109 [ Time Frame: Up to 2 years ] Adverse events will be assessed and severity assigned by using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0. Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) ... [More >>]

Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma (INFINITE)

Primary Outcome Measures Overall Survival [ Time Frame: 60 months ] Time to death (from any cause) from randomization Secondary Outcome Measures Survival rate [ Time Frame: 60 months ] Number of deaths (from any ... [More >>]

Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers

Primary Outcome Measures Pre-treatment Prognostic Algorithm Validation [ Time Frame: 4 years ] The primary outcome will be to prospectively validate a pre-treatment prognostic algorithm to predict survival for MPM patients. Secondary Outcome Measures Evaluation of Molecular Tests Base on RNA Expression [ Time Frame: 4 years ] A secondary outcome will be to evaluate molecular tests that are based ... [More >>]

Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery

Primary Outcome Measures Incidence of adverse events per National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 [ Time Frame: Up to 30 days ] The frequency of toxicities will be tabulated by grade across all dose levels and cycles. All subjects who receive any study treatment will be considered ... [More >>]

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

Primary Outcome Measures Number of treatment-emergent adverse events [ Time Frame: Up to 12 months ] Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug. Maximum tolerated dose or pharmacologically active dose (PAD) of INCAGN02390 (Part 1 only) [ Time Frame: Up to approximately 1 month ] PAD ... [More >>]

Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies

Primary Outcome Measures Number of Participants With Adverse Events evaluated with NCI CTC AE, version 4.0 [ Time Frame: 60 months ] Safety evaluation Secondary Outcome Measures Clinical response [ Time Frame: 60 months ] Clinical response to T-cell infusion, especially change of tumor volume will be evaluated by comparing disease identified by computed tomography, ... [More >>]

Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma

Primary Outcome Measures Incidence and severity of adverse events as assessed by CTCAE v.5.0 [ Time Frame: 6 weeks ] number and severity of adverse events according to NCI CTCAE v.5.0 Secondary Outcome Measures Response Evaluation Criteria in Solid Tumors (RECIST) [ Time Frame: 6 weeks ] tumor response scored by RECIST criteria Immune-related Response Evaluation ... [More >>]

DENdritic Cell Immunotherapy for Mesothelioma (DENIM)

Primary Outcome Measures Overall survival rate [ Time Frame: from randomisation to study end (the last visit for the last subject participating in the study and the last data collection point completed) assessed in up to 102 weeks ] The primary outcome measure of this study is to evaluate the overall survival ... [More >>]

Last update: January 19, 2018. 04:57:31 pm.